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Abstract
Introduction Microsatellite instability (MSI) predict response to anti-PD1 immunotherapy in colorectal cancer (CRC). CRCs 
with MSI have higher infiltration of immune cells related to a better survival. Elevated Microsatellite Alterations at Tetranu-
cleotides (EMAST) is a form of MSI but its association with PD-L1 expression and immune-cell infiltration is not known.
Methods A consecutive, observational cohort of patients undergoing surgery for CRC. EMAST and clinicopathological 
characteristics were investigated against PD-L1, as well as CD3 and CD8 expression in the invasive margin or tumour centre 
(Immunoscore). Difference in survival between groups was assessed by log rank test.
Results A total of 149 stage I–III CRCs patients, with a median follow up of 60.1 months. Patients with PD-L1+ tumours 
(7%) were older (median 79 vs 71 years, p = 0.045) and had EMAST+ cancers (OR 10.7, 95% CI 2.2–51.4, p = 0.001). 
Recurrence-free survival was longer in cancers with PD-L1+ immune cells (HR 0.35, 95% CI 0.16–0.76, p = 0.008, inde-
pendent of EMAST) and high Immunoscore (HR 0.10, 95% CI 0.01–0.72, p = 0.022). Patients expressing PD-L1 in immune 
cells had longer disease-specific survival (HR 0.28, 95% CI 0.10–0.77, p = 0.014).
Conclusions Higher Immunoscore (CD3/CD8 cells) and expression of tumour PD-L1 is found in CRCs with EMAST. 
Lymphocytic infiltrate and peritumoral PD-L1 expression have prognostic value in CRC.
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Abbreviations
CRC  Colorectal cancers
EMAST  Elevated Microsatellite Alterations at Selected 
Tetranucleotides
MSI  Microsatellite instability
Introduction
Colorectal cancers (CRCs) with deficient mismatch repair 
(MMR) are often hypermutated, have microsatellite insta-
bility (MSI), are associated with improved prognosis and is 
defined to the ‘immunogenic’ class of consensus molecu-
lar subtypes [1]. Notably, MSI is determined by a panel of 
microsatellite markers, commonly mononucleotides, accord-
ing to established guidelines [2]. However, an alternative 
form of MSI is found in tetranucleotide-based microsatellites 
and labelled Elevated Microsatellite Alterations at Selected 
Tetranucleotides (EMAST) [3, 4]. Currently, the prognos-
tic value, molecular mechanisms and clinical implications 
of EMAST are unclear. EMAST was linked in vitro with 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0026 2-020-02573 -0) contains 
supplementary material, which is available to authorized users.
 * Kjetil Søreide 
 ksoreide@mac.com
1 Gastrointestinal Translational Research Unit, Stavanger 
University Hospital, Stavanger, Norway
2 Department of Clinical Medicine, University of Bergen, 
Bergen, Norway
3 Department of Pathology, Stavanger University Hospital, 
Stavanger, Norway
4 Department of Chemistry, Bioscience and Environmental 
Engineering, University of Stavanger, Stavanger, Norway
5 Department of Gastrointestinal Surgery, Stavanger University 
Hospital, Stavanger, Norway
1628 Cancer Immunology, Immunotherapy (2020) 69:1627–1637
1 3
downregulation of MSH3, a member of MMR specifically 
implicated with repair of long indels [4]. This proposed 
mechanism has not been confirmed across patient series, 
with a previous study from our group refuting an associa-
tion between MSH3 and EMAST [5]. Prognostic data on 
EMAST is also scarce. In a previous study, we found that 
patients with EMAST+ were older, frailer and less likely to 
have recurrence from CRC [6].
CRCs with MSI are associated with a higher production 
of neoantigens and consequent immune system activation 
[7]. The understanding of host immune system and its rel-
evance for cancer control has evolved across several tumour 
types yet with varying potential for therapeutic interven-
tion and effect on disease trajectory [7]. In colorectal cancer 
(CRC), data suggest that type and density of immune cells 
are related to survival and may be used to improve TNM-
staging by incorporating an Immunoscore [8, 9]. Hence, the 
immune cells infiltrating in the tumour microenvironment 
have a functional role in CRC, although understanding of 
associated factors related to this peritumoral activation is 
poor at present.
Cancer immunosurveillance of the adaptive immune 
system may be disturbed through various mechanisms [10]. 
One example is the activation of immune checkpoints such 
as the receptor-ligand complex PD-1/PD-L1 that dampens 
the immune response and cause T-cell exhaustion [7, 11, 
12]. Data suggesting that PD-1 blockade therapy potentially 
benefits the MMR/MSI subsets of CRCs and other cancers 
[13–15], introduced immunotherapy for clinical use [16]. 
However, selection of patients who may benefit and respond 
is currently uncertain. Further, scarce evidence exists to date 
on the association of PD-L1 expression and prognosis and 
survival, both within and outside the predictive subsets of 
CRC. Data regarding the relationship between EMAST and 
PD-L1 expression and the associated T-cell infiltration are 
lacking.
The aim of the present study was thus to describe the 
prevalence of PD-L1 expression, Immunoscore, their rela-
tionship with MSI/EMAST and their relevance towards 




Patients were consecutively recruited during the 
01/2013–05/2015 period at Stavanger University Hospital 
(SUH), Norway. Norway has a universal health care cover-
age for all citizens and the university hospital serves a pri-
mary catchment region of about 370,000 inhabitants. With 
no selection or referral bias in the health care system, the 
study cohort can be considered as population representative 
and generalizable to similar regions in Northern Europe.
The present study cohort is part of an ongoing prospec-
tive project (ACROBATICC) approved by the regional eth-
ics committee (REK Helse Vest: 2012/742) and registered 
on clinicaltrials.gov (NCT01762813) [17]. All consecutive 
patients amenable to curative intent surgery, aged ≥ 18 years 
of age and who could provide written informed consent were 
eligible for inclusion into ACROBATICC. This observa-
tional cohort study of patients presenting with operable stage 
I–III disease and is reported according to the STROBE [18] 
and the REMARK [19] guidelines for biomarker studies.
Histopathology
All cancers were staged by an experienced pathologist fol-
lowing guidelines published in the 7th edition of the AJCC 
staging manual [20]. Proximal tumour location is intended 
as the region between caecum and transverse colon, while 
distal is intended as the region between the splenic flexure 
and sigmoid colon.
EMAST and MSI analysis
Analyses of EMAST and MSI, including primer sequences 
and PCR conditions, are described previously [21, 22]. 
Briefly, formalin-fixed paraffin blocks selected by an expe-
rienced pathologist were sectioned for DNA extraction. 
Macrodissection of areas indicated by the pathologist was 
employed where necessary to enrich for tumour cells. Auto-
mated DNA extraction was carried out using AllPrep DNA/
RNA FFPE kit (Qiagen, Hilden, Germany) on a QiaCUBE 
instrument (Qiagen), according to manufacturer’s instruc-
tions. Nucleic acid concentration and purity were measured 
on a NanoDrop 2000 (ThermoFischer scientific, Waltham, 
USA). Two separate multiplex PCR reactions (one for each 
MSI and EMAST) were set up for tumour and normal DNA 
in each patient. TypeIT microsatellite (Qiagen) master mix, 
together with a blending of 5 × 5′-fluorescently labelled 
primer pairs was used for each reaction. The primers for 
MSI were specific for the quasimonomorphic mononucleo-
tides BAT-26, NR-21, NR-24 and NR-27, while the EMAST 
marker panel consisted of MYCL1, D8S321, D9S242, 
D20S82, and D20S85. To define a tumour as MSI-H, at least 
2/5 markers needed to be unstable in their respective panels.
Immunohistochemistry
Paraffin sections consecutive to the haematoxylin–eosin 
(H&E) sections were cut to 2 µm and mounted onto Super-
frost Plus slides (Menzel, Braunschweig, Germany). Anti-
gen retrieval and antibody dilution were optimised for each 
induvial staining. All antibody protocols were optimized 
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before study onset. Paraffin sections consecutive to the 
haematoxylin–eosin (H&E) sections were cut to 2 µm and 
mounted onto Superfrost Plus slides (Menzel, Braunsch-
weig, Germany). Slides were incubated at 60 °C for 1 h 
and then transferred to a Dako Omnis (Dako, Glostrup, 
Denmark) instrument. CD3 (Dako, Clone F7.2.38) 
was used at a dilution of 1:75 and visualised by EnVi-
sion FLEX, High pH (Dako Omnis) (GV80011-2). CD8 
(Dako, Clone C8/144B) was used at a dilution of 1:50 and 
visualized by EnVision FLEX, High pH (Dako Omnis) 
(GV80011-2).with EnVision FLEX+ Mouse LINKER 
(Dako Omnis) (GV82111-2) signal amplification.
EnVision FLEX Antibody Diluent (Dako, K800621-
2) was used as diluent. Pre-treatment time was 20 min at 
97 °C using EnVision FLEX Target Retrieval Solution, 
High pH (50 ×) (Dako Omnis) (GV800). Both antibodies 
were incubated for 20 min. Hematoxylin (Dako Omnis) 
(GC80811-2) was used as counterstain.
PD-L1 IHC 22C3 pharmDx (Dako SK00621-2) was 
used strictly according to manufacturer’s recommendation 
on a Dako Autostainer Link 48 instrument.
Scoring of PD‑L1 expression
PD-L1 expression (Fig.  1) was assessed independently 
by two experienced pathologists (DL and EG), blinded 
to patients’ other characteristics and each other results, 
on whole sections. Membranous staining was regarded as 
positive, and staining intensity was not evaluated. PD-L1 in 
tumour cells was scored as positive or negative using ≥ 5% 
positive as cut-off, based on previous studies [14, 23].
For PD-L1 expression on peritumoral immune cells, the 
percentage of positive cells were evaluated in the visually 
most positive area of 1 mm2 in the invasive margins of the 
tumour on the scanned slides (same area for both patholo-
gists). In cases with > 10% discordance between the patholo-
gists, the slides were reviewed together, until consensus was 
reached. For expression in less than 10% of the immune 
cells, discordance of < 5% was accepted.
The cut-off for positive or negative classifications of 
patients based on PD-L1 expression in peritumoral immune 
cells, was determined experimentally.
Receiver operator characteristics (ROC) curve analy-
sis was used to determine cut-offs for PD-L1 expression 
Fig. 1  Immunohistochemistry of PD-L1. 20X magnification view of a immune PD-L1−/tumour PD-L1−. b Immune PD-L1−/tumour PD-L1+. 
c Immune PD-L1+/tumour PD-L1−. d Immune PD-L1+ / tumour PD-L1+. Scale bar represents 100 μm
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in immune cells, with disease-specific death and disease 
recurrence as the endpoints. The optimal cut-off point in 
both ROC curve analysis corresponded to the 25th per-
centile and was therefore chosen as the discriminant cut-
off to dichotomize expression of immune cells PD-L1 into 
positive/negative.
Immune scoring of CD3 and CD8 markers
All the sections were scanned at 40 × magnification using 
Leica SCN400 slide scanner (Leica Microsystems, Wetzlar, 
Germany) and uploaded onto the image analysis software 
 Visiopharm® (Hoersholm, Denmark). Tumour centre and 
invasive margin areas were marked manually on whole slide 
images and the same areas were used for the CD3 and CD8 
stained sections. Using Bayesian optimisations [24], an 
algorithm was developed to identify and label CD3+ and 
CD8+ T-cells in both regions.
Relative quantification of positive cells was obtained 
by dividing the Visiopharm-measured area of positive 
label by the estimation of mean area of a lymphocyte 
(60 µm2), thereby approximating the number of CD3+ and 
CD8+ T-cells per square millimetres (cells/mm2). All the 
cases were inspected, and unspecific staining and artefacts 
were manually removed from the analyses where appro-
priate. For individual CD3/CD8 analysis, patients were 
assigned either a “low” or “high” score for each individual 
staining (CD3 and CD8), in each tumour location (tumour 
centre and invasive margin and IM), using the 75th percen-
tile as a threshold. This created four categories (CD3 and 
CD8, in tumour centre and invasive margin as either high 
or low).
The Immunoscore was calculated as described else-
where [8]. Briefly, the densities (in cells/mm2) of CD3+ and 
CD8+ cells in both tumour centre and invasive margin were 
first converted into percentiles, and then the mean value of 
the four percentiles calculated. An Immunoscore of “Low”, 
“Intermediate” or “High” was then assigned to each patient 
according to their mean percentile scores, with cut-offs as 
0–25%, 25–70%, and 70–100% respectively, as described 
in [8].
Collection of clinical data and follow up
Clinical measurements as well as follow up data (cause and 
date of death, date of recurrence) were retrieved from the 
electronic patient records. Patients’ surveillance after sur-
gery was according to the national guidelines as an interval-
based serum CEA (quarterly) and imaging (e.g. a biannual 
CT-chest and US liver for the first 3 years, then annually) for 
up to 5 years after surgery. Colon cancers were usually fol-
lowed up by general practitioners while rectal cancers were 
seen by gastrointestinal surgeons in the hospital outpatient 
clinics. Any suspected recurrence or deviation on imag-
ing were worked up in-hospital and consulted in multidis-
ciplinary team meetings, where applicable. The patients’ 
electronic health records were queried for any documented 
events, and follow-up for this study was completed as of 24th 
September 2019.
Definition of survival endpoints
Recurrence-free survival (RFS) was defined as time from 
primary surgery until first clinical evidence (histologically 
confirmed or image-based) of recurrent disease. Disease-
specific survival (DSS) was defined as time from primary 
surgery and death imputable to CRC. Survival was assessed 
for overall survival (OS) defined as time from primary sur-
gery to death of any cause.
Statistical analyses
All statistical tests were done using IBM SPSS Statistics 
for Windows, Version 25.0 (IBM Corporation, Armonk, 
NY, USA). Associations between categorical variables 
were tested with Chi-square (or Fischer’s exact test, where 
appropriate) method and reported with odds ratios and 95% 
confidence interval (95% CI). Spearman’s rho or Pearson 
tests were used for correlations between continuous/ordinal 
variables, where appropriate. Mann–Whitney U test was 
used to compare differences in continuous or ordinal vari-
ables between groups. Inter-coder reliability score for PD-L1 
evaluation was estimated using the KALPHA extension for 
SPSS and expressed as Krippendorff’s alpha (α).
The Kaplan–Meier method with log rank comparison of 
factors was used to investigate survival curves differences 
between groups and are given as (months difference [95% 
CI]). Univariable proportional hazards are given in hazard 
ratios (HR) with 95% CI. All tests were two-tailed and a p 
value < 0.050 considered as statistically significant.
Results
The study cohort included 149 stage I–III CRC patients who 
underwent surgery with curative intent (Fig. 2). Patients’ 
descriptive parameters are included in Table 1.
PD‑L1 expression and EMAST
Of the 11 patients classified as PD-L1+ in tumour cells, 
nine were diagnosed with right-side CRC (82%, no rectum, 
p = 0.111) and were EMAST+ (82%; Table 2). Inter-coder 
reliability score for PD-L1 expression in tumour cells was 
high (Krippendorff’s α = 0.93; 95% CI 0.83–0.99). A weak 
correlation was also seen between expression of tumoral 
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Fig. 2  Flowchart of inclusion/
exclusion criteria. CRC denotes 
colorectal cancer; IHC denotes 
immunohistochemistry
Table 1  Variables associated 
with EMAST status
N = 149
Bold values indicate statistical significance (P < 0.050)
*One missing
Total n, (%) EMAST− n = 99 (66) EMAST+ n = 50 (34) p
Age < 0.001
 Median (range) 72 (37–92) 70 (37–91) 77.5 (50–92)
 ≤ 72 75 (50) 60 (80) 15 (20)
 > 72 74 (50) 39 (53) 35 (47)
Sex < 0.001
 Male 65 (44) 54 (83) 11 (17)
 Female 84 (56) 45 (54) 39 (46)
Localisation < 0.001
 Colon 124 (83) 74 (60) 50 (40)
 Rectum 25 (17) 25 (100) 0 (0)
Within colon < 0.001
 Right 70 (57.5) 25 (36) 45 (64)
 Left 54 (43.5) 49 (90) 5 (10)
Grade* < 0.001
 High 39 (26) 15 (38) 24 (62)
 Low 109 (74) 83 (76) 26 (24)
Stage 0.234
 I 51 (34) 30 (59) 21 (41)
 II 50 (34) 33 (66) 17 (34)
 III 48 (32) 36 (75) 12 (25)
MSI < 0.001
 MSS 105 (70.5) 97 (92) 8 (8)
 MSI-H 44 (29.5) 2 (5) 42 (95)
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PD-L1 and total number of unstable markers analysed for 
both EMAST and MSI (Fig. 3; p = 0.001). A higher number 
of markers from the two panels combined were indeed 
unstable in PD-L1+ tumours (median 9/10 vs 1/10 mark-
ers, p = 0.001), when dichotomised accordingly (Suppl. 
Table 1). Tumour PD-L1+ patients were significantly older 
(79 vs 71 years, p = 0.045) and had lower preoperative lev-
els of serum albumin (33.6 vs 38.1 g/L, p = 0.011) (Suppl. 
Table 1). All PD-L1+ tumours (11/11, 100%) were in the 
colon, while none of the 25 rectum tumours scored positive 
(p = 0.212).
In peritumoral infiltrating immune cells, the rate of 
PD-L1 expression was higher than in tumour cells (Fig. 1). 
No statistically significant association was found between 
expression of PD-L1 in immune cells and patients’ age, 
EMAST status or number of unstable markers (Suppl. 
Table 1). Again, a significant but small correlation was 
found between % PD-L1 and CD3/CD8 in immune cells, 
albeit not in the case of CD3 in the invasive margin. The two 
ROC analyses for determination of ideal cut-off value of % 
PD-L1 positive immune cells had AUC = 0.698, p = 0.012 
with disease-specific death and AUC = 0.648, p = 0.018 with 
disease recurrence as endpoint (data not shown). The 25th 
percentile cut-off showed no difference in the distribution 
among colon and rectum cancers, of which 73% and 76% 
Table 2  Associations with 
immune markers and EMAST 
status
Bold values indicate statistical significance (P < 0.050)
N = 149 Total n, (%) EMAST− n = 99 
(66)
EMAST+ n = 50 
(34)
OR (95% CI) p
PD-L1 in tumour cells 10.7 (2.2–51.4) 0.001
 Low 138 (93) 97 (98) 41 (82)
 High 11 (7) 2 (2) 9 (18)
PD-L1 in immune cells 1.0 (0.5–2.2) 0.973
 Low 39 (26) 26 (26) 13 (26)
 High 110 (74) 73 (74) 37 (74)
Immune cells in tumour centre
 CD3+ 2.37 (1.1–5.1) 0.025
  Low 112 (75) 80 (81) 32 (64)
  High 37 (25) 19 (19) 18 (36)
 CD8+ 2.4 (1.1–5.1) 0.025
  Low 112 (75) 80 (81) 32 (64)
  High 37 (25) 19 (19) 18 (36)
Immune cells in invasive margin
 CD3+ 3.22 (1.5–7.0) 0.002
  Low 112 (75) 82 (83) 30 (60)
  High 37 (25) 17 (17) 20 (40)
 CD8+ 2.4 (1.1–5.1) 0.025
  Low 112 (75) 80 (81) 32 (64)
  High 37 (25) 19 (19) 18 (36)
Immunoscore n.c. 0.020
 Low 31 (21) 24 (24) 7 (14)
 Interm 79 (53) 56 (57) 23 (46)
 High 39 (26) 19 (19) 20 (40)
Fig. 3  Correlation matrix of immune-related variables. For pure ordi-
nal variables (marked by the notation “cells/mm2”), Pearson correla-
tion coefficient is shown. For all other variable Spearman R-O tests 
were used. Bold correlation coefficients are significant (p < 0.05)
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showed PD-L1-positive immune cells, respectively. Inter-
coder reliability score for PD-L1 expression in immune 
cells was relatively high (Krippendorff’s α = 0.81; 95% CI 
0.72–0.88).
Immune cell types, Immunoscore and EMAST status
Higher density of CD3+ and CD8+ cells in tumour cen-
tre and invasive margins were found in EMAST-positive 
patients (Table 2).
Immunoscore was distributed into low (n = 31, 21%), 
intermediate (79, 53%) and high (n = 39, 26%) categories, 
respectively. EMAST-positive patients were proportionally 
more represented in the higher Immunoscore subclasses 
(Table 2). As expected, Immunoscore correlated strongly 
with each individual CD3+ and CD8+ tally. A stronger 
relationship between Immunoscore and % of PD-L1+ in 
immune (Spearman 0.365, p < 0.001) rather than in tumour 
cells (0.262, p = 0.001) was found (Fig. 3).
Tumours with PD-L1+ tumours had significantly higher 
counts of CD3 and CD8 in the invasive margin, as well as 
CD8, but not CD3 in the tumour centre (Suppl. Table 1).
Patients with PD-L1+ immune cells had significantly 
higher counts of CD3 and CD8 in both the invasive mar-
gin and tumour centre (Suppl. Table  1). Both immune 
PD-L1+ (p < 0.001) and tumour PD-L1+ (p = 0.037) patients 
were significantly associated with a high Immunoscore.
Risk of recurrence and recurrence‑free survival
During the follow up period, a total of 26 (17.4%) patients 
experienced recurrent disease. Eight recurrences (31%) 
were in the liver, eight in the lungs, 7 (27%) were local 
recurrences, and one (4%) each for bone, peritoneum and 
brain.
Generally, higher numbers of infiltrating lymphocytes 
correlated with lower risk of disease recurrences (Suppl. 
Figure 1).
A significant difference was found between the catego-
ries of the Immunoscore for RFS (Fig. 4; Table 3). No 
Fig. 4  Survival analyses comparing prognostic groups. Kaplan-Meier 
analysis of a recurrence-free survival (RFS) of immune PD-L1+/− 
groups. b RFS of immune PD-L1+/− groups, stratified for EMAST 
status. c RFS of Immunoscore groups (low-intermediate-high). d Dis-
ease-specific survival (DSS) of immune PD-L1+/− groups
1634 Cancer Immunology, Immunotherapy (2020) 69:1627–1637
1 3
significant association between tumour PD-L1 and rate 
(p = 0.690) or time to recurrence (p = 0.520) were recorded. 
Of the patients with negative immune-PD-L1 expres-
sion, 12 (31%) presented with recurrent disease patients 
against 14 (13%) of those with immune-PD-L1+ . Patients 
with PD-L1+ immune cells had longer estimated RFS (72 
[68–75] vs 59 [49–69] months, p = 0.006) than immune-PD-
L1− patients, independently of EMAST status (p = 0.041 
and 0.021 in EMAST− and EMAST+ cases, respectively) 
(Fig. 4).
Overall and disease‑specific survival
At the time of final follow-up, a total of 35 (23%) patients 
had died. Of those, 15 (43%) were CRC-related deaths. 
Median follow up length was 68.8 months (range 0.4–79.6) 
from primary surgery to death or right-censoring.
Only nodal status (pN0 vs pN+ or stage I–II vs stage III) 
was associated with OS in univariate analyses (Table 3). 
When stratified according to the three Immunoscore levels, 
a high Immunoscore had significantly longer overall sur-
vival than low (74 vs 60 [50–70] months, p = 0.008), but not 
intermediate (74 [69–79] vs 68 [63–72] months, p = 0.192). 
No difference was noted in survival time when patients 
were divided according to tumour PD-L1 expression, 
whilst patients with a higher PD-L1 proportion in immune 
cells had longer DSS (log rank p = 0.009; Fig. 4; Table 3). 
When stratified for EMAST status, patients with PD-L1+ in 
immune cells had better DSS in the EMAST-negative group 
(log rank p = 0.033) but not in the EMAST+ group (log rank 
p = 0.107).
Discussion
In the current study, CRC having EMAST correlated 
with a higher count of intra- and peritumoral CD3+ and 
CD8+ T-cells and a higher Immunoscore compared to CRC 
cancers with no EMAST. Also, PD-L1 expression occurred 
both in immune cells and in tumour cells in CRCs, specifi-
cally those with EMAST and MSI.
While the patterns of expression in tissue does not 
directly translate into functional ability, there are several 
observations we would point out as being of interest.
First, expression of PD-L1 showed a dual role according 
to its localisation in this study. Tumour cell-confined PD-L1 
correlated with EMAST and generally increasing degree of 
MSI, while immune cells PD-L1 did not. EMAST indepen-
dently correlated with a generally higher immunogenicity, 
with higher levels of CD3+ , CD8+ and PD-L1+ in tumour 
cells. This is generally in accordance with the relationship 
between MSI, high mutational burden, generation of tumour 
neoantigens, and activation of the immune system [7, 25]. 
Notably, one study previously reported an association with 
EMAST and CD8+ but not CD4+ T-cells infiltration in 
tumour [26]. In a previous report, a link between EMAST 
and older age and a frailer phenotype in patients with 
EMAST positive cancers was found [6]. These observations, 
pertinent to a cumulative increase in genetic abnormalities 
(e.g. EMAST, MSI, mutation burden) during physiological 
and cellular senescence, may weigh in on the picture of a 
neoantigen-rich tumour microenvironment. Of note, while 
the distribution of immune cells expressing PD-L1 seemed 
comparable between colon and rectum cancers, PD-L1-ex-
pressing tumours were exclusively found in colon cancers. 
This may further confirm a relationship between PD-L1 and 
instability at microsatellites, as both MSI and EMAST are 
more prevalent in the colon.
A direct relationship between high Immunoscore and high 
PD-L1 expression in both tumour and immune cells was 
also shown in the present study. Tumours with low counts 
for CD3+ and CD8+ cells are associated with less overall 
(tumour/immune) PD-L1 expression. PD-L1 was here found 
to be rarely expressed in tumour cells, and strictly con-
nected to EMAST status, while more diffuse in infiltrating 
immune cells. This is concordant with recent reports placing 
tumour PD-L1 rates generally under 15–20% of CRCs, and 
immune PD-L1 consistently higher [27–32]. These obser-
vations may suggest that induction of PD-L1 is regulated 
Table 3  Univariate analyses for survival
Bold values indicate statistical significance (P < 0.050)
*Numbers in parentheses are events/total number of cases
Term HR 95% CI p
Recurrence-free survival (26/149)*
 PD-L1 in immune cells 0.35 0.16–0.76 0.008
 PD-L1 in tumour cells 0.53 0.07–3.87 0.527
 Immunoscore (int. + low vs 
high)
0.10 0.01–0.72 0.022
 pN (N0 vs N+) 6.94 2.91–16.52 < 0.001
 EMAST 0.35 0.12–1.02 0.054
Disease-specific survival (15/149)*
 PD-L1 in immune cells 0.28 0.10–0.77 0.014
 PD-L1 in tumour cells 0.98 0.13–7.44 0.982
 Immunoscore (int. + low vs 
high)
0.03 0.00–3.37 0.145
 pN (N0 vs N+) 229.76 1.44–36788.19 0.036
 EMAST 0.51 0.14–1.79 0.289
Overall survival (35/149)*
 PD-L1 in immune cells 0.61 0.30–1.23 0.165
 PD-L1 in tumour cells 1.78 0.63–5.05 0.277
 Immunoscore (int. + low vs 
high)
0.42 0.16–1.08 0.073
 pN (N0 vs N+) 3.17 1.62–6.19 0.001
 EMAST 1.04 0.52–2.09 0.915
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by different pathways in immune and tumour cells. On one 
side, EMAST (as MSI) tumours, due to their higher load of 
tumour neoantigens are possibly subject to a more vigorous 
cytotoxic immune response, and endogenously expressing 
PD-L1 to counteract it. In non-EMAST tumours with high 
Immunoscore, otherwise, modulation of immune response 
is achieved by expression of PD-L1 on immune cells, in a 
mechanism also referred to as adaptive immune resistance 
[33, 34]. Finally, tumours having both low Immunoscore and 
PD-L1 expression on immune cells lack an immune reaction 
in the tumour microenvironment and present with higher rate 
of recurrences, sooner.
Prognostically, only expression of PD-L1 in the peritu-
moral cells proved discriminant in both rate of- and time 
to recurrences, as well as for disease-specific survival. In 
terms of RFS, the association was independent of EMAST 
status and comparable to that of Immunoscore, suggest-
ing that immune expression of PD-L1 contributes to the 
protective effect of tumour immunosurveillance. Tumour 
PD-L1 was not associated with any of the survival end-
points examined. In contrast to Immunoscore, there is 
scarce data on the prognostic significance of PD-L1 
expression in CRC. The relationship between tumour-
expressed PD-L1 and tumour-infiltrating lymphocytes is 
being investigated in multiple cancers [35, 36]. The focus 
is however usually on tumour-expressed PD-L1, because 
of its predictive value for immunotherapy, while there is 
discordance on its prognostic role [32, 37, 38]. PD-L1 
positivity on peritumoral immune cells, on the other hand, 
is generally a sign of an active immune response and thus 
associated with improved survival [31, 32, 39, 40].
A limitation of the present study is the limited size 
of the cohort, with only 11 patients scoring positive for 
tumour PD-L1, therefore limiting the statistical power. 
However, the idea of modern personalized medicine is 
to identify particular subgroups with potential for refined 
therapy. Prevalence of tumour PD-L1 in MSI CRCs and 
the low (15–20%) incidence of the subgroup, warrant 
expansion of the cohort in order to investigate the find-
ings in larger cohorts and refined sub populations. A fur-
ther limit is the cut-off determination for immune PD-L1 
expression. Derived from ROC analysis for recurrence and 
disease-specific death, which are time-dependent variable, 
this method may only apply to the present cohort, in the 
elapsed follow up time. Indeed, a range of methods of 
PD-L1 scoring and subgrouping are described in the lit-
erature, including variation in antibodies used, without 
a generalised consensus. In the present study, the cut-off 
value used for PD-L1 expression in tumour cells (5%) was 
based on previous studies [14, 23, 29], including original 
anti-PD-1 immunotherapy clinical trials.
The current study correlates PD-L1 expression in 
tumour cells with EMAST. Moreover, the findings add to 
the mounting data on PD-L1 expression in peritumoral 
immune infiltrate and Immunoscore as prognostic factors in 
CRC. Finally, this study supports the differentiation between 
tumour- and immune cell expression of PD-L1 as representa-
tive of two distinct mechanisms of immune resistance.
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